Selected article for: "group comparison and survival rate"

Author: Qiu, Yingshan; Lam, Jenny K. W.; Leung, Susan W. S.; Liang, Wanling
Title: Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside
  • Document date: 2016_9_20
  • ID: 04pp3lv0_74
    Snippet: One complication of using TGF-β as the molecular target of RNAi is related to its physiological role in maintaining immune and cellular homeostasis. It has a role in tumor suppression as suggested by the finding that specific inhibition of TGF-β in mouse stromal fibroblasts results in spontaneous carcinoma formation in the adjacent epithelium [226] . As a result, targeting the downstream effectors of TGF-β may offer the therapeutic benefit of .....
    Document: One complication of using TGF-β as the molecular target of RNAi is related to its physiological role in maintaining immune and cellular homeostasis. It has a role in tumor suppression as suggested by the finding that specific inhibition of TGF-β in mouse stromal fibroblasts results in spontaneous carcinoma formation in the adjacent epithelium [226] . As a result, targeting the downstream effectors of TGF-β may offer the therapeutic benefit of inhibiting the TGF-β-mediated fibrotic response while preserving the major physiological function of the profibrotic cytokine [227] . CTGF is a key molecule that regulates fibroblast mitosis and promotes collagen deposition in pulmonary fibrosis induced by TGF-β. A non-viral delivery system consists of poly(dimethylamino)ethylmethacrylate (PDMAEMA) and its copolymer with poly(methylether-methacrylate-ethyleneglycol) [PMAPEG] was used to incorporate and form complexes with siRNA targeting CTGF. After intratracheal administration, significant reduction of CTGF expression, collagen deposition and inflammatory cytokines (IL-6, TNF-α and TGF-β) production were observed in bleomycin-induced lung fibrosis animal model. More importantly, the survival rate of the animals treated with siRNA targeting CTGF was significantly increased in comparison with the group treated with scrambled siRNA [225] .

    Search related documents:
    Co phrase search for related documents
    • animal model and delivery system: 1, 2, 3, 4
    • animal model and downstream effector: 1
    • animal model and inflammatory cytokine: 1, 2, 3, 4, 5, 6, 7, 8
    • animal model and intratracheal administration: 1, 2
    • animal model and key molecule: 1
    • animal model and lung fibrosis: 1, 2, 3, 4
    • animal model and molecular target: 1
    • animal model and physiological function: 1
    • animal model and physiological role: 1
    • animal model and pulmonary fibrosis: 1, 2, 3, 4, 5, 6
    • animal model and significant reduction: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • animal model and specific inhibition: 1, 2
    • animal model and survival rate: 1, 2, 3, 4, 5, 6, 7, 8
    • animal model and TGF β: 1, 2, 3, 4, 5
    • animal model and therapeutic benefit: 1